Arcutis Biotherapeutics announced that John Smither, who served as Arcutis’ first CFO from 2019 to 2021, has been appointed interim CFO effective August 31. He is replacing Scott Burrows, who is leaving the company as of such date to pursue an external opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARQT:
- Arcutis Appoints Interim Chief Financial Officer (CFO)
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Arcutis, Huadong announce strategic collaboration, agreement for Roflumilast
- Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
- Arcutis Biotherapeutics price target lowered to $50 from $65 at TD Cowen